国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Stability Indicating Rp-Hplc Method for Estimation of Migalastatin Capsule Dosage Form

S Pavan Kumar, K Swaroopa Rani, P Sathya Sowmya, G Somsekhar

A stability-indicating reverse phase high performance liquid chromatography method was developed and validated for Migalastat. The wavelength selected for quantitation was 275 nm. The method has been validated for linearity, accuracy, precision, robustness, limit of detection and limit of quantitation. Linearity was observed in the concentration range of 10-50 μg/ml for Migalastat. For RP-HPLC, the separation was achieved by XTerra C 18 (150×4.6 mm) 5 μm column using 0.1% Tri fluro acetic acid: Methanol:Acetonitrile (20:40:40. v/v) as mobile phase with flow rate 0.7 ml/ min. The retention time of Migalastat was found to be 2.6 min respectively. During force degradation, drug product was exposed to hydrolysis (acid and base hydrolysis), H2O2, thermal degradation and photo degradation. In thermal degradation the highest amount of drug was found to be 4.69%. The developed methods were simple, specific and economic, which can be used for simultaneous estimation of Migalastat in capsule dosage form.

Aim and objective: Development of new RP-HPLC method for the estimation of Migalastat in capsule dosage form and then validation of the method.

Method: RP-Hplc Method, stability indicating RP-HPLC method for estimation of migalostat in capsule dosage form validation of the method developed using validation parameters.

Results: The assay of Migalastat was performed with Capsule and the % assay was found to be 100.25 which show that the method is useful for routine analysis.The linearity of Migalastat was found to be linear with a correlation coefficient of 0.999, which shows that the method is capable of producing good sensitivity. The acceptance criteria of precision is RSD should be not more than 2.0% and the method show precision 0.6 for Migalastat which shows that the method is precise. The acceptance criteria of intermediate precision is RSD should be not more than 2.0% and the method show precision 0.2 for Migalastat which shows that the method is repeatable when performed in different days also. The accuracy limit is the percentage recovery should be in the range of 98.0% - 102.0%. The total recovery was found to be 100.41% for Migalastat. The validation of developed method shows that the accuracy is well within the limit, which shows that the method is capable of showing good accuracy and reproducibility. The acceptance criteria for LOD and LOQ are 3 and 10. The LOD and LOQ for Migalastat was found to be 2.98 and 9.97.The robustness limit for mobile phase variation and flow rate variation are well within the limit, which shows that the method is having good system suitability and precision under given set of conditions. The acceptance criteria for degradation studies are less than 15%. The degradation results are within the limit.

Conclusion: The estimation of Migalastat was done by RP-HPLC.